This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents (ISAR-TEST6)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2012 by Deutsches Herzzentrum Muenchen.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Deutsches Herzzentrum Muenchen Identifier:
First received: February 11, 2010
Last updated: May 7, 2012
Last verified: May 2012
The aim of this prospective, randomized study is to compare the efficacy and safety of biodegradable polymer based limus-eluting stents (BPDES) with permanent polymer based everolimus eluting stents (PPDES).

Condition Intervention Phase
Coronary Heart Disease Device: Nobori® (Biodegradable polymer limus-eluting stents) Device: Xience-V® (Permanent polymer limus-eluting stent) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Prospective, Randomized Trial of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coatings

Further study details as provided by Deutsches Herzzentrum Muenchen:

Primary Outcome Measures:
  • A composite endpoint of cardiac death, myocardial infarction related to the target vessel or revascularisation related to the target lesion. [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • The composite of all cause mortality or myocardial infarction [ Time Frame: 6-8 months ]
  • Stent thrombosis [ Time Frame: 6-8 months ]
  • Late luminal loss [ Time Frame: 6-8 months ]
  • Binary angiographic restenosis [ Time Frame: 6-8 months ]

Estimated Enrollment: 2010
Study Start Date: February 2010
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: BPLES
Biodegradable polymer limus-eluting stents
Device: Nobori® (Biodegradable polymer limus-eluting stents)
due randomization biodegradable polymer limus-eluting stents will be implanted
Other Names:
  • Nobori®
  • ISAR G2
Active Comparator: PPLES
Permanent polymer limus-eluting stent
Device: Xience-V® (Permanent polymer limus-eluting stent)
due randomization permanent polymer limus-eluting stent will be implanted
Other Name: Xience-V®

Detailed Description:
Restenosis affects 20-40% of de novo coronary lesions treated with bare-metal stents. Although it is often considered a benign process, recent data indicate that in-stent restenosis has a negative impact on long-term survival of patients treated with coronary stents. Drug eluting stents have emerged as the most effective strategy for the prevention of restenosis. A large number of studies showed that drug-eluting stents significantly reduce in-stent restenosis and the subsequent need for target vessel revascularisation compared with bare-metal stents. Available evidence shows that all 3 limus drugs − rapamycin, everolimus and biolimus − are very effective in suppressing neointima formation after coronary stenting. Drugs are fully released within a few weeks from the majority of current DES. However, most of the DES use permanent polymers, which continue to remain in the vessel wall even after accomplishing their drug-release mission. Their permanent presence may be associated with persistent inflammatory reaction and delayed neointimal proliferation and vessel thrombosis. Clinical trial evidence with biodegradable polymer DES is still limited, but there are great expectations that this DES technology might be the dominant one in the years to come.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50% stenosis located in native coronary vessels.
  • Written, informed consent by the patient or her/his legally-authorized representative for participation in the study.
  • In women with childbearing potential a negative pregnancy test is mandatory.

Exclusion Criteria:

  • Target lesion located in the left main trunk.
  • In-stent restenosis of DES.
  • Cardiogenic shock.
  • Malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than 12 months or that may result in protocol non-compliance.
  • Known allergy to the study medications: rapamycin, everolimus, biolimus, stainless steel or cobalt chrome.
  • Inability to take dual antiplatelet therapy for at least 6 months.
  • Pregnancy (present, suspected or planned) or positive pregnancy test.
  • Previous enrollment in this trial.
  • Patient's inability to fully cooperate with the study protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01068106

Deutsches Herzzentrum Muenchen
Munich, Germany, 80636
Klinikum rechts der Isar der Technischen Universitaet Muenchen
Munich, Germany, 81675
Sponsors and Collaborators
Deutsches Herzzentrum Muenchen
Study Chair: Julinda Mehilli, MD Deutsches Herzzentrum Muenchen
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Deutsches Herzzentrum Muenchen Identifier: NCT01068106     History of Changes
Other Study ID Numbers: GE IDE No. S03010
Study First Received: February 11, 2010
Last Updated: May 7, 2012

Additional relevant MeSH terms:
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases processed this record on June 22, 2017